---
title: "Entyvio (vedolizumab) in ulcerative colitis: Pharmacology questions"
description: "Pharmacology questions on Entyvio (vedolizumab) in ulcerative colitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pharmacokinetics. Questions: Do the Entyvio Pen and Entyvio IV give similar drug levels? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/pharmacology"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab) in ulcerative colitis: Pharmacology questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)

Pharmacology questions that apply to every indication of Entyvio are on [Entyvio (vedolizumab), all indications: Pharmacology](https://www.evicenter.com/medical-information/entyvio/pharmacology).

## Pharmacokinetics

<a id="entyvio-pen-vs-iv-levels"></a>

### Do the Entyvio Pen and Entyvio IV give similar drug levels?

Applies to: Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

> “Table 3. Mean ± SD Vedolizumab Concentrations in Patients* with Ulcerative Colitis 
> and Crohn’s Disease
> Patient
> Population
> Weeks 0, 2, and 6
> ENTYVIO 300 mg
> Intravenously
> After Week 6 to 52
> ENTYVIO 300 mg Intravenously
> Every 8 Weeks
> Trough Serum Concentration
> at Week 6 (mcg/mL)
> Trough Serum Concentration
> at Week 46† (mcg/mL)
> Ulcerative Colitis
> 26.3 ± 12.9
> (N=210)
> 11.2 ± 7.2
> (N=77)
> Crohn’s Disease
> 27.4 ± 19.2
> (N=198)
> 13.0 ± 9.1
> (N=72)
> * Data from patients in UC Trials I and II and CD Trials I and III with pharmacokinetic data available; data 
> from patients with anti-vedolizumab antibody were excluded.
> †  Steady-state trough serum concentration.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

> “In ulcerative colitis and Crohn’s disease patients, administered 300 mg ENTYVIO as a 
> 30-minute intravenous infusion on Weeks 0 and 2, followed by 108 mg ENTYVIO as a 
> subcutaneous injection every 2 weeks starting from Week 6, the mean steady state serum 
> trough concentrations were 35.8 mcg/mL (SD ± 15.2) and 31.4 mcg/mL (SD ± 14.7), 
> respectively.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

> “The bioavailability of vedolizumab following a 108 mg single-dose subcutaneous injection 
> relative to a 300 mg single-dose intravenous infusion in healthy subjects was approximately 
> 75%. Following a 108 mg single-dose subcutaneous injection in healthy subjects, the median 
> Tmax was 7 days with a range of 3 to 14 days and the mean Cmax was 15.4 mcg/mL (SD ± 3.2).”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

> “Vedolizumab SC dosing at 108 mg every 2 weeks was calculated to provide generally comparable drug exposure to that achieved with vedolizumab IV 300 mg every 8 weeks based on average serum vedolizumab concentrations at steady state. A previous population PK model was used to perform the simulations.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=Vedolizumab%20SC%20dosing%20at%20108,used%20to%20perform%20the%20simulations.)

> “*The mean steady state serum trough concentration for the ENTYVIO Pen was 35.8 mcg/mL (SD ±15.2).”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=%2AThe%20mean%20steady%20state%20serum,was%2035.8%20mcg%2FmL%20%28SD%20%C2%B115.2%29.)

> “PK data for IV and pen were not directly compared and do not imply efficacy or safety.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Efficacy in Moderate to Severe Ulcerative Colitis, captured 2026-11-13](https://www.entyviohcp.com/ulcerative-colitis-efficacy#accordion-87ee588919-item-fcda56c722:~:text=PK%20data%20for%20IV%20and,not%20imply%20efficacy%20or%20safety.)

Note: Table 3 gives IV trough concentrations, including the every-8-week steady state at Week 46; the efficacy page compares the two routes by simulated average concentration at steady state. In the second passage the two trough values are, respectively, for ulcerative colitis (35.8 mcg/mL) and Crohn's disease (31.4 mcg/mL).

## Related pages
- [Medical information: Entyvio (vedolizumab): Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)
- [Indication](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/guidelines)
